J. Bullock

发表

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

Lessons Learned: Dose Selection of Small Molecule–Targeted Oncology Drugs

Atiqur Rahman, J. Bullock, Qi Liu, 2016, Clinical Cancer Research.

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Pazdur, A. Al-Hakim, R. Justice, 2015, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

C. Garnett, L. Burke, R. Pazdur, 2012, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease

R. Pazdur, R. Justice, Liang Zhao, 2015, Clinical Cancer Research.

Induction of imatinib metabolism by hypericum perforatum.

W. Jusko, Patrick F. Smith, J. Bullock, 2004, Blood.

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype Typhi

Ronald N. Jones, Patrick F. Smith, S. Bhavnani, 2005, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

J. Holst, Yan-Ling He, J. Foley, 2007, Journal of clinical pharmacology.

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach

J. Bullock, Tiffany Lin, S. Bilic, 2017, Journal of clinical pharmacology.

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

R. Pazdur, R. Justice, R. Sridhara, 2010, Clinical Cancer Research.

Folo with U.S

R. Pazdur, R. Sridhara, Shenghui Tang, 2010 .

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies Report from the Fda

R. Pazdur, R. Lechleider, R. Justice, 2022 .

The Challenges and Opportunities of Rare Disease Drug Development

J. Bullock, 2022 .

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

Lei Nie, Dhananjay D. Marathe, Richard Pazdur, 2015, Clinical Cancer Research.

Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R‐, and S‐Methadone

B. Kearney, Patrick F. Smith, J. Flaherty, 2004, Pharmacotherapy.

The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

W. Jusko, Patrick F. Smith, J. Bullock, 2004, Pharmacotherapy.

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.

R. Pazdur, M. Rothmann, C. Ko, 2014, The oncologist.

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

R. Pazdur, R. Justice, C. Ko, 2014, Clinical Cancer Research.

Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐QT Study

J. Mason, C. Sanabria, C. Rayner, 2018, Clinical and translational science.

Development of a Pharmacokinetic and Bayesian Optimal Sampling Model for Individualization of Oral Busulfan in Hematopoietic Stem Cell Transplantation

L. Shaw, Patrick F. Smith, J. Bullock, 2006, Therapeutic drug monitoring.

Preparing pharmacy graduates for traditional and emerging career opportunities.

S. Meyer, R. Nemire, E. F. Fiese, 2009, American journal of pharmaceutical education.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

Shiew-Mei Huang, Ping Zhao, Lawrence J Lesko, 2012, Biopharmaceutics & drug disposition.

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

Yan-Ling He, S. Schwartz, W. Dole, 2008, International journal of clinical pharmacology and therapeutics.

Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer

J. Marier, B. Rich, J. Bullock, 2022, British journal of clinical pharmacology.

Future Pharmacy Graduates - Making More Opportunities Than We See White Paper Prepared for the American Association of Colleges of Pharmacy (AACP) Curricular Change Summit March 2009 Authors:

S. Meyer, J. Bullock, G. Brazeau, 2009 .

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

R. Pazdur, V. Goodman, J. Gobburu, 2008, Clinical Cancer Research.

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Pazdur, A. Khandelwal, F. Borrego, 2012, Clinical Cancer Research.

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

R. Pazdur, R. Lechleider, R. Justice, 2008, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

R. Pazdur, Jessica J. Hawes, Todd R. Palmby, 2013, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

C. Garnett, L. Burke, R. Pazdur, 2012, Clinical Cancer Research.

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

R. Pazdur, R. Justice, C. Ko, 2014, Clinical Cancer Research.